2023 World Conference on Lung Cancer (Posters)-EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC

EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the peri-operative and mid-term oncologic outcomes of surgery as a form of local consolidation for advanced non-small cell lung cancer (NSCLC) after targeted therapy. Between March 2018 and October 2022, 74 patients who had received pulmonary resection for stage IIIB-C or IV NSCLC after targeted therapy were analyzed. The mean age of the patients was 56.2 years, with 32.4% being male. The initial stages were IIIB in 10 patients, IIIC in 1 patient, and IV in 63 patients. The main mutations were EGFR in 53 patients, ALK in 19 patients, and ROS1 in 2 patients. The types of metastasis sites included the brain, bones, lymph nodes, intrathoracic organs, and multiple organs. The median interval from the initiation of targeted therapy to the operation was 12.8 months. The types of operations performed included lobectomies, bi-lobectomies, and sub-lobar resections. Complete resection was achieved in 95.9% of patients, and there were no operative mortalities. Complications were observed in 18 patients. Complete remission on the surgical specimen was noted in 10 patients. The median peri-operative targeted kinase inhibitor (TKI) treatment duration was 30.0 months. The 3-year progression-free survival and overall survival after surgery were 46.4% and 81.4%, respectively. The study concludes that pulmonary resection for advanced NSCLC after targeted therapy is feasible and promising for avoiding or delaying progression. However, further trials are needed to study the long-term benefits of pulmonary resection on oncologic outcomes after targeted therapy.

Asset Subtitle

Byung Jo Park

Meta Tag

Speaker Byung Jo Park

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

peri-operative

oncologic outcomes

surgery

NSCLC

targeted therapy

pulmonary resection

mutations

metastasis sites

complete resection

progression-free survival